Diabetic Nephropathy: Modern Principles of Classification, Diagnostics and Features of Sugar-Reducing Therapy
DOI:
https://doi.org/10.51699/ijhsms.v2i7.2251Abstract
The article is devoted to modern approaches to the treatment of diabetes mellitus complicated by kidney damage. Diabetes mellitus is the most important problem of modern medicine, which is primarily due to the high prevalence of the disease among the working-age population. Diabetic nephropathy is one of the severe chronic complications of diabetes, which increases the disability and mortality of patients. Diabetic nephropathy is the main cause of the development of end-stage renal failure in developed countries and eventually affects about 30% of patients. Kidney damage in patients with diabetes occurs in 6-7% of cases out of the total number of nephropathies in patients receiving treatment in a specialized nephrological department of a multidisciplinary hospital. The first manifestations of diabetic nephropathy develop 3-4 years after the onset of the disease, and reach their peak in 15-20 years. The concept of «chronic kidney disease» includes kidney damage regardless of the primary diagnosis and is characterized by such basic diagnostic criteria as urinary albumin excretion and glomerular filtration rate values, which are markers of kidney damage. Methods for preventing the progression of diabetic nephropathy include general measures to change the lifestyle, control of glycemia and blood pressure, correction of lipid metabolism disorders in combination with nephroprotective therapy. Currently, when choosing therapy in patients with type 2 diabetes mellitus in combination with chronic kidney disease, along with taking metformin, preference is given to sodium-glucose cotransporter type 2 inhibitors and glucagon-like peptide-1 receptor agonists with a nephroprotective effect.
Downloads
References
World Health Organization 2019. URL: https://www.who.int/diabetes/global-report/en/.
Джураева А. Ш., Бадридинова Б. К. Сравнительный Анализ Качества Жизни Больных Принимающих Программный Гемодиализ //Центрально Азиатский Эндокринологический Журнал. – 2022. – Т. 2. – №. 2.
Badridinova B. K. Comparative Analysis Of Program Hemodialysis Efficiency And Impact On Quality Of Life //Uzbek Scholar Journal. – 2022. – Т. 11. – С. 186-192.
Bommer C., Heesemann E., Sagalova V., Manne-Goehler J., Atun R., Bärnighausen T. et al. The global economic burden of diabetes in adults aged 20-79 years: a cost-of-illness study // Lancet Diabetes Endocrinol. 2017; 5: 423-430. URL: https://doi.org/10.1016/S2213-8587(17)30097-9.
Badridinova B. K. Comparative Analysis Of Program Hemodialysis Efficiency And Impact On Quality Of Life //Uzbek Scholar Journal. – 2022. – Т. 11. – С. 186-192
Badridinova B. K. Risk factors for the development of diabetic nephropathy In patients with type 1 diabetes //ДОКТОР АХБОРОТНОМАСИ ВЕСТНИК ВРАЧА DOCTOR’S HERALD. – 2020. – С. 40.
Яхёева Х. Ш. //Сахарный Диабет 2-Го Типа У Детей И Подростков Бухарской Области
Биология и интегративная медицина, 139-145, 2021Kimmelstiel P., Wilson C. Intercapillary lesion in the glomeruli of the kidney // Am. J. Pathol. 1936; 12: 82-97.
Remuzzi G., Schieppati A., Ruggenenti P. Clinical practice. Nephropathy in Patients with Type 2 Diabetes // N. Engl. J. Med. 2002; 346 (15): 1145-1151.
Алгоритмы специализированной медицинской помощи больным сахарным диабетом: клин. рек. / Под ред. И. И. Дедова, М. В. Шестаковой, А. Ю. Майорова // Сахарный диабет. 9-й вып. М.: 2019. 212 с. [Algorithms of specialized medical care for patients with diabetes mellitus: wedge. rivers. / Pod red. I. I. Dedova, M. V. Shestakovoy, A. Yu. Mayorova // Sakharnyy diabet. 9-y vyp. M.: 2019. P. 212.]
Худоёрова Д. Р. Прогноз И Профилактика Диабетической Нефропатии //Research Journal Of Trauma And Disability Studies. – 2023. – Т. 2. – №. 4. – С. 75-84.
Шестакова М. В., Шамхалова М. Ш., Ярек-Мартынова И. Я. и др. Сахарный диабет и хроническая болезнь почек: достижения, нерешенные проблемы и перспективы лечения // Сахарный диабет. 2011; 1: 81-88. [Shestakova M. V., Shamkhalova M. Sh., Yarek-Martynova I. Ya. i dr. Diabetes Mellitus and Chronic Kidney Disease: Achievements, Unresolved Issues and Treatment Prospects // Sakharnyy diabet. 2011; 1: 81-88.]
Orzikulova Sh. A. (2022). Relationship Of New Markers Of Kidney Damage And Vascular Status In Patients With Arterial Hypertension. Eurasian Medical Research Periodical, 7, 161–166.
Захарьина О. А., Тарасов А. А., Бабаева А. Р. Актуальные аспекты медикаментозной профилактики и лечения диабетической ангиопатии // Лекарственный вестник. 2012; 5 (45): 14-22. [Zakhar'ina O. A., Tarasov A. A., Babayeva A. R. Actual aspects of drug prevention and treatment of diabetic angiopathy // Lekarstvennyy vestnik. 2012; 5 (45): 14-22.]
М.Ш. Тоиров, Ш.А. Орзиқулова. Таълим Ва Ривожланиш Таҳлил. Анализ Роли Артериальной Гипертонии И Нарушений Липидного Обмена В Развитии И Прогрессировании Хронической Болезни Почек У Больных Гипертонической Болезнью. Volume: 02 Issue: 10 |Oct- 2022 ISSN: 2181-2624
Mogensen C. E., Christensen C. K., Vittinghus E. The stages in diabetic renal disease. With emphasis on the stage of incipient diabetic nephropathy // Diabetes. 1983; 32 (2): 64-78.
Шестакова М. В. Диабетическая нефропатия: фатальное или предотвратимое осложнение? // Рус. мед. журнал. http://www.rmj.ru/2007/3. [Shestakova M. V. Diabetic nephropathy: a fatal or preventable complication? // Rus. med. zhurnal. http://www.rmj.ru/2007/3.]
Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury // Kidney Int Suppl. 2012; Issue 1: 1-126.
Lim S., Eckel R. H., Koh K. K. Clinical implications of current cardiovascular outcome trials with sodium glucose cotransporter-2 (SGLT2) inhibitors // Atherosclerosis. 2018; 272: 33-40.
Handelsman Y. Rationale for the early use of sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes // Advances in Therapy. 2019; 36 (10): 2567-2586.
Wanner C., Inzucchi S. et al. Empaglifozin and progression of kidney disease in type 2 diabetes // N. Engl J. Med. 2016; 375: 323–334.
Jakher H., Chang T. I., Tan M., Mahaffey K. W. Canagliflozin review – safety and efficacy profile in patients with T2DM // Diabetes Metab. Syndr. Obes. 2019; 12: 209-15. DOI: 10.2147/DMSO.S184437.
Prischl F. C., Wanner C. Renal Outcomes of Antidiabetic Treatment Options for Type 2 Diabetes-A Proposed MARE Definition // Kidney Int. Rep. 2018; 3 (5): 1030-8. DOI: 10.1016/j.ekir.2018.04.008.
